PTC THERAPEUTICS INC (PTCT) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:PTCT • US69366J2006

74.68 USD
+2.32 (+3.21%)
At close: Feb 6, 2026
74.68 USD
0 (0%)
After Hours: 2/6/2026, 4:53:36 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to PTCT. PTCT was compared to 524 industry peers in the Biotechnology industry. Both the profitability and the financial health of PTCT get a neutral evaluation. Nothing too spectacular is happening here. PTCT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make PTCT suitable for growth investing!


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • PTCT had positive earnings in the past year.
  • In the past year PTCT had a positive cash flow from operations.
  • PTCT had negative earnings in each of the past 5 years.
  • In the past 5 years PTCT always reported negative operating cash flow.
PTCT Yearly Net Income VS EBIT VS OCF VS FCFPTCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

  • With an excellent Return On Assets value of 28.43%, PTCT belongs to the best of the industry, outperforming 97.90% of the companies in the same industry.
  • PTCT has a better Return On Invested Capital (41.48%) than 99.05% of its industry peers.
Industry RankSector Rank
ROA 28.43%
ROE N/A
ROIC 41.48%
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTCT Yearly ROA, ROE, ROICPTCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

  • PTCT has a better Profit Margin (42.25%) than 97.71% of its industry peers.
  • PTCT has a Operating Margin of 52.45%. This is amongst the best in the industry. PTCT outperforms 99.81% of its industry peers.
  • PTCT has a Gross Margin of 96.83%. This is amongst the best in the industry. PTCT outperforms 96.76% of its industry peers.
  • PTCT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 52.45%
PM (TTM) 42.25%
GM 96.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
PTCT Yearly Profit, Operating, Gross MarginsPTCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • PTCT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for PTCT has been increased compared to 1 year ago.
  • Compared to 5 years ago, PTCT has more shares outstanding
  • Compared to 1 year ago, PTCT has a worse debt to assets ratio.
PTCT Yearly Shares OutstandingPTCT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PTCT Yearly Total Debt VS Total AssetsPTCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 2.10 indicates that PTCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.10, PTCT is doing good in the industry, outperforming 67.94% of the companies in the same industry.
  • PTCT has a debt to FCF ratio of 3.38. This is a good value and a sign of high solvency as PTCT would need 3.38 years to pay back of all of its debts.
  • PTCT has a better Debt to FCF ratio (3.38) than 92.56% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.38
Altman-Z 2.1
ROIC/WACC5.67
WACC7.31%
PTCT Yearly LT Debt VS Equity VS FCFPTCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

  • PTCT has a Current Ratio of 2.32. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
  • PTCT has a worse Current ratio (2.32) than 72.14% of its industry peers.
  • A Quick Ratio of 2.26 indicates that PTCT has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.26, PTCT is doing worse than 70.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 2.26
PTCT Yearly Current Assets VS Current LiabilitesPTCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 277.07%, which is quite impressive.
  • The Revenue has grown by 97.54% in the past year. This is a very strong growth!
  • PTCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.32% yearly.
EPS 1Y (TTM)277.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.39%
Revenue 1Y (TTM)97.54%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%7.23%

3.2 Future

  • The Earnings Per Share is expected to grow by 23.80% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 17.29% on average over the next years. This is quite good.
EPS Next Y263.62%
EPS Next 2Y32.9%
EPS Next 3Y30.18%
EPS Next 5Y23.8%
Revenue Next Year124.43%
Revenue Next 2Y7.77%
Revenue Next 3Y13.92%
Revenue Next 5Y17.29%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PTCT Yearly Revenue VS EstimatesPTCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
PTCT Yearly EPS VS EstimatesPTCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 10.29, which indicates a very decent valuation of PTCT.
  • Based on the Price/Earnings ratio, PTCT is valued cheaply inside the industry as 98.09% of the companies are valued more expensively.
  • PTCT is valuated cheaply when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
  • The Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 10.29
Fwd PE N/A
PTCT Price Earnings VS Forward Price EarningsPTCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

  • 98.66% of the companies in the same industry are more expensive than PTCT, based on the Enterprise Value to EBITDA ratio.
  • PTCT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PTCT is cheaper than 99.05% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.5
EV/EBITDA 5.69
PTCT Per share dataPTCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PTCT's earnings are expected to grow with 30.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y32.9%
EPS Next 3Y30.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PTCT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PTC THERAPEUTICS INC

NASDAQ:PTCT (2/6/2026, 4:53:36 PM)

After market: 74.68 0 (0%)

74.68

+2.32 (+3.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-24
Inst Owners105.27%
Inst Owner Change0.6%
Ins Owners0.73%
Ins Owner Change10.25%
Market Cap6.00B
Revenue(TTM)1.78B
Net Income(TTM)751.72M
Analysts78.18
Price Target83.91 (12.36%)
Short Float %13.15%
Short Ratio6.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)68.83%
Min EPS beat(2)23.33%
Max EPS beat(2)114.33%
EPS beat(4)3
Avg EPS beat(4)1164.83%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)5
Avg EPS beat(8)562.98%
EPS beat(12)5
Avg EPS beat(12)357.38%
EPS beat(16)5
Avg EPS beat(16)260.9%
Revenue beat(2)2
Avg Revenue beat(2)7.12%
Min Revenue beat(2)2.58%
Max Revenue beat(2)11.67%
Revenue beat(4)3
Avg Revenue beat(4)147.37%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)5
Avg Revenue beat(8)76.88%
Revenue beat(12)7
Avg Revenue beat(12)50.21%
Revenue beat(16)10
Avg Revenue beat(16)38.94%
PT rev (1m)0.65%
PT rev (3m)23.52%
EPS NQ rev (1m)76.71%
EPS NQ rev (3m)86.43%
EPS NY rev (1m)2.71%
EPS NY rev (3m)30.52%
Revenue NQ rev (1m)11.75%
Revenue NQ rev (3m)36.08%
Revenue NY rev (1m)1.31%
Revenue NY rev (3m)5.15%
Valuation
Industry RankSector Rank
PE 10.29
Fwd PE N/A
P/S 3.37
P/FCF 8.5
P/OCF 8.38
P/B N/A
P/tB N/A
EV/EBITDA 5.69
EPS(TTM)7.26
EY9.72%
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)8.78
FCFY11.76%
OCF(TTM)8.91
OCFY11.93%
SpS22.16
BVpS-1.94
TBVpS-7.9
PEG (NY)0.04
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 28.43%
ROE N/A
ROCE 52.5%
ROIC 41.48%
ROICexc 822.48%
ROICexgc N/A
OM 52.45%
PM (TTM) 42.25%
GM 96.83%
FCFM 39.64%
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score7
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.38
Debt/EBITDA 1.9
Cap/Depr 31.38%
Cap/Sales 0.58%
Interest Coverage 163.67
Cash Conversion 74.07%
Profit Quality 93.81%
Current Ratio 2.32
Quick Ratio 2.26
Altman-Z 2.1
F-Score7
WACC7.31%
ROIC/WACC5.67
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.39%
EPS Next Y263.62%
EPS Next 2Y32.9%
EPS Next 3Y30.18%
EPS Next 5Y23.8%
Revenue 1Y (TTM)97.54%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%7.23%
Revenue Next Year124.43%
Revenue Next 2Y7.77%
Revenue Next 3Y13.92%
Revenue Next 5Y17.29%
EBIT growth 1Y813.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year827.35%
EBIT Next 3Y63.62%
EBIT Next 5YN/A
FCF growth 1Y375.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y419.28%
OCF growth 3YN/A
OCF growth 5YN/A

PTC THERAPEUTICS INC / PTCT FAQ

What is the ChartMill fundamental rating of PTC THERAPEUTICS INC (PTCT) stock?

ChartMill assigns a fundamental rating of 5 / 10 to PTCT.


What is the valuation status for PTCT stock?

ChartMill assigns a valuation rating of 6 / 10 to PTC THERAPEUTICS INC (PTCT). This can be considered as Fairly Valued.


Can you provide the profitability details for PTC THERAPEUTICS INC?

PTC THERAPEUTICS INC (PTCT) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for PTCT stock?

The Price/Earnings (PE) ratio for PTC THERAPEUTICS INC (PTCT) is 10.29 and the Price/Book (PB) ratio is -38.5.